Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK112 plus chemotherapy versus durvalumab plus chemotherapy as first-line treatment for advanced biliary tract cancer
CTR20243164Phase 3Active
- Sponsor
- Akeso, Inc.
- Start
- Oct 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of ivonescimab in biliary cancer, cholangiocarcinoma (CCA), gallbladder cancer, sponsored by Akeso, Inc.. Started Oct 2024; status: active.
02
Drugs
ivonescimab
03
Conditions
biliary cancercholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on CTR20243164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243164.